Analysis of interleukin‐13 receptor α2 expression in human pediatric brain tumors

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.20470PMID 15329913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor α2 chain in vivo

  2003cited by this paper
• Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.

  2002cited by this paper
• IL-13 Receptor-Targeted Cytotoxin Cancer Therapy Leads to Complete Eradication of Tumors with the Aid of Phagocytic Cells in Nude Mice Model of Human Cancer1

  2002cited by this paper
• IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.

  2002cited by this paper
• Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.

  2002cited by this paper
• In Vivo Overexpression of IL-13 Receptor α2 Chain Inhibits Tumorigenicity of Human Breast and Pancreatic Tumors in Immunodeficient Mice

  2001cited by this paper
• The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.

  2001cited by this paper
• Mutation and functional analysis of IL-13 receptors in human malignant glioma cells.

  2001cited by this paper
• Pediatric glial tumors

  2001cited by this paper
• One-, two-, and three-color whole-mount in situ hybridization to Drosophila embryos.

  2001cited by this paper
• Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.

  2001cited by this paper
• Correspondence re: B. H. Joshi et al., interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res., 60: 1168-1172, 2000.

  2001cited by this paper
• In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.

  2001cited by this paper
• Interleukin‐13 receptor as a unique target for anti‐glioblastoma therapy

  2001cited by this paper
• Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.

  2001cited by this paper
• Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.

  2000cited by this paper
• Sensitization of Cancer Cells to Interleukin 13-Pseudomonas Exotoxin-Induced Cell Death by Gene Transfer of Interleukin 13 Receptor α Chain

  2000cited by this paper
• Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas.

  2000cited by this paper
• Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review).

  1998cited by this paper
• Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors

  1997cited by this paper
• Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells.

  1997cited by this paper
• Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.

  1996cited by this paper
• Receptor for Interleukin (IL) 13 Does Not Interact with IL4 but Receptor for IL4 Interacts with IL13 on Human Glioma Cells*

  1996cited by this paper
• Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.

  1995cited by this paper
• Tumor antigens in astrocytic gliomas

  1995cited by this paper
• In situ hybridization with digoxigenin-labeled RNA probes: facts and artifacts.

  1995cited by this paper
• Expression and localization of urokinase-type plasminogen activator receptor in human gliomas.

  1994cited by this paper
• Human neurological cancer cells express interleukin‐4 (IL‐4) receptors which are targets for the toxic effects of IL4‐pseudomonas exotoxin chimeric protein

  1994influential reference

• Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice.

  2026cites this paper
• Radiotherapy plus neoadjuvant and concomitant IL-13Rα2-directed immunotoxin therapy for diffuse intrinsic pontine glioma

  2026cites this paper
• Development of a quadruple-conjugated carbon dot nanomodel for targeted glioma therapy

  2026cites this paper
• Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors.

  2025cites this paper
• Medulloblastoma: biology and immunotherapy

  2025cites this paper
• Nanoparticle-based delivery systems for targeted therapy in brain tumors: Progress, challenges and perspectives (Review)

  2025cites this paper
• IL-13/IL-13Rα2 axis promotes proliferation of angiosarcoma cells

  2025cites this paper
• CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials

  2024cites this paper
• Treatment advances in high-grade gliomas

  2024cites this paper
• Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update

  2023cites this paper
• Prognostic risk of immune-associated signature in the microenvironment of brain gliomas

  2023cites this paper
• Advanced T and Natural Killer Cell Therapy for Glioblastoma

  2023cites this paper
• Chimeric Antigen Receptor T Cells in Glioblastoma—Current Concepts and Promising Future

  2023cites this paper
• IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma

  2022cites this paper
• Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy

  2022cites this paper
• Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma

  2022cites this paper
• Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers

  2022cites this paper
• Proteomics and metabolomics approach in adult and pediatric glioma diagnostics.

  2022cites this paper
• Locoregional infusion of IL13Rα2-specific immunotoxins in children and adults with high-grade glioma.

  2022cites this paper
• Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours

  2021cites this paper
• Advances in immunotherapeutic targets for childhood cancers: a focus on glypican-2 and B7-H3.

  2021cites this paper
• CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma

  2021cites this paper
• A narrative review of research progress on drug therapies for glioblastoma multiforme

  2021cites this paper
• Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

  2021cites this paper
• CAR T-Cell Therapy for CNS Malignancies

  2020cites this paper
• Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.

  2020cites this paper
• Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13Rα2-Promoted Invasion and Metastasis in Cancer Cells

  2020influential citation
• Immunotherapy in Pediatric Solid Tumors—A Systematic Review

  2019cites this paper
• Challenges and Opportunities for Childhood Cancer Drug Development

  2019cites this paper
• CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?

  2018cites this paper
• IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma

  2018cites this paper
• Adoptive Cell Therapy in Treating Pediatric Solid Tumors

  2018cites this paper
• Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway

  2018cites this paper
• Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme

  2017cites this paper
• Signaling pathways and mesenchymal transition in pediatric high-grade glioma

  2017cites this paper
• Immunotoxin Therapy for Brain Tumors

  2017cites this paper
• Identification of gene networks in childhood epilepsy: evidence from focal cortical dysplasia

  2016cites this paper
• Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.

  2016cites this paper
• TARGETED THERAPY – A HOPE FOR MALIGNANT GLIOMA TREATMENT

  2016cites this paper
• Engineered T cells: the promise and challenges of cancer immunotherapy

  2016cites this paper
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  2015cites this paper
• Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.

  2014cites this paper
• Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy

  2014cites this paper
• Cytokine Induction of VCAM-1 but Not IL13Rα2 on Glioma Cells: A Tale of Two Antibodies

  2014cites this paper
• Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis

  2013cites this paper
• The potential for genetically altered microglia to influence glioma treatment.

  2013cites this paper
• Toxin-Based Targeted Therapy for Malignant Brain Tumors

  2012cites this paper
• Tumor cell targeted delivery by specific peptide-modified mesoporous silica nanoparticles

  2012cites this paper
• Increased expression of tumor-associated antigens in pediatric and adult ependymomas: implication for vaccine therapy

  2012cites this paper
• A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

  2012cites this paper
• Cancer Therapy : Preclinical Stem-like Tumor-Initiating Cells Isolated from IL 13 R a 2 Expressing Gliomas Are Targeted and Killed by IL 13-Zetakine – Redirected T Cells

  2012cites this paper
• Pediatric diffuse intrinsic pontine glioma : can optimism replace pessimism ? Review

  2012cites this paper
• IL-13 receptor-directed cancer vaccines and immunotherapy.

  2012cites this paper
• Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells

  2012cites this paper
• Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?

  2012cites this paper
• Molecularly-Targeted Gold-Based Nanoparticles for Cancer Imaging and Near-Infrared Photothermal Therapy

  2011cites this paper
• Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

  2011cites this paper
• The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy.

  2011cites this paper
• A Novel Combination Immunotherapy for Cancer by IL-13Rα2–Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models

  2011cites this paper
• Expression of IL-13Rα2 in liver cancer cells and its effect on targeted therapy of liver cancer

  2010cites this paper
• Vaccine therapy with dendritic cells transfected with Il13ra2 mRNA for glioma in mice.

  2010cites this paper
• NFAT and AP1 are Essential for the Expression of a Glioblastoma Multiforme Related IL-13Ra2 Transcript

  2010cites this paper
• Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells.

  2010cites this paper
• Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models

  2010cites this paper
• Cellules stromales mésenchymateuses comme vecteurs cellulaires de nanoparticules : un nouvel outil thérapeutique des tumeurs cérébrales

  2010cites this paper
• Decreasing expression of the interleukin-13 receptor IL-13Ralpha2 in treated recurrent malignant gliomas.

  2010cites this paper
• cDNA clone, prokaryotic expression and purification of human interleukin-13 receptor {alpha}2 chain

  2009cites this paper
• Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma.

  2008cites this paper
• Targets for active immunotherapy against pediatric solid tumors

  2008cites this paper
• Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas

  2008cites this paper
• Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines

  2007cites this paper
• Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells

  2007influential citation
• Immunotoxins for Glioma Therapy

  2007cites this paper
• Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.

  2007cites this paper
• Candidate genes for the progression of malignant gliomas identified by microarray analysis

  2007cites this paper
• Multiforme : Implications for Targeted Therapies 2 in Glioblastoma α Expression of Interleukin-13 Receptor

  2007influential citation
• Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.

  2007cites this paper
• Antigenic Profiling of Glioma Cells to Generate Allogeneic Vaccines or Dendritic Cell–Based Therapeutics

  2007cites this paper
• Oncolytic viruses for the treatment of malignant glioma

  2006cites this paper
• Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.

  2006cites this paper
• Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy*

  2006cites this paper
• Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy

  2006cites this paper
• Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiforme

  2006cites this paper
• Intratumoral Therapy with IL13-PE38 Results in Effective CTL-Mediated Suppression of IL-13Rα2-Expressing Contralateral Tumors

  2006cites this paper
• Intratumoral Therapy with IL 13-PE 38 Results in Effective CTL-Mediated Suppression of IL-13 R A 2-Expressing ContralateralTumors

  2006cites this paper
• Gene therapy for malignant glioma

  2006cites this paper
• Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.

  2005cites this paper
• Expression of IL-13Ra2 gene in human brain tumors

  2005cites this paper
• Evidence That IL-13Rα2 Chain in Human Glioma Cells Is Responsible for the Antitumor Activity Mediated by Receptor-Directed Cytotoxin Therapy

  2005cites this paper
• Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.

  2005cites this paper
• Small molecule and monoclonal antibody therapies in neurooncology.

  2005cites this paper
• Pediatric High-grade Glioma: Molecular Genetic Clues for Innovative Therapeutic Approaches

  2005cites this paper